AzTrials
AzTrials

ObesityAVDNCT03149965

Maternal Body Mass Index and Anovaginal Distance

A study testing transperineal ultrasound in people with Obesity and Pregnancy, run by Linkoeping University.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The hypothesis was that the anovaginal distance (AVD), defined as the distance between the anal mucosa and the vaginal wall at the middle level of the anal canal, is higher in obese women compared with normal weight women. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Obesity, Pregnancy
What is being tested?
transperineal ultrasound
Could I receive a placebo?
No, everyone receives an active treatment
How many people
207 participants
Where
No sites listed yet
Study dates
2 Oct 2014to 31 Mar 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Active labor according to the Swedish definition; two out of three of the following criteria must be present: painful contractions (two to three contractions in every ten minutes), cervix shortened and dilated > one centimeter (cm) and/or rupture of membranes.
  • The maximum cervix dilatation was of seven centimeters.
  • The participant had to be aged ≥18 years
  • The participant had to be proficient in the Swedish language

Who cannot join

  • Not in active labor,
  • Cervix dilatation of more than seven centimeters,
  • Age <19
  • Not speaking Swedish.

About this study

Official title: Maternal Body Mass Index and Anovaginal Distance in Active Phase of Labor at Term Pregnancy

The hypothesis was that the anovaginal distance (AVD), defined as the distance between the anal mucosa and the vaginal wall at the middle level of the anal canal, is higher in obese women compared with normal weight women. Measuring the AVD with transperineal ultrasound has been shown to have a high interobserver agreement.

This study aimed to establish if there was a difference in AVD measured by transperineal ultrasound between obese and normal weight women in active phase of labor at term pregnancy. The second aim was to present normal values for the AVD in active phase of labor at term pregnancy.

Read the detailed description

This is a prospective cohort study including primiparous women in active phase of labor at term pregnancy on admission at the delivery ward at Linkoping University hospital. The study period was between October 2014 and March 2016. Term pregnancy was defined as ≥ 37 - ≤ 42 gestational weeks. The women had to be in active labor according to the Swedish definition; two out of three of the following criteria must be present: painful contractions (two to three contractions in every ten minutes), cervix shortened and dilated > one centimeter (cm) and/or rupture of membranes. The maximum cervix dilatation allowed for inclusion was seven cm. Further the participant had to be proficient in the Swedish language and aged ≥18 years. All participants were given written and verbal information of the study. The verbal consent to participate was documented in the women´s medical record.

A total number of 207 women were included in the study. There was no information available about whether the women declined participation or if they were not invited to participate. 333 women were excluded due to prematurity, cervix dilatation > seven cm when the women were signed in at the delivery ward, younger than 18 years or not speaking satisfactory Swedish language. After woman's informed consent, the AVD was measured with transperineal ultrasound. The standardized method consisted of placing the vaginal probe at a right angle to the posterior vaginal distal wall, and in a transversal scanning plane. All examinations were done with the patient in the lithotomy position. The internal anal sphincter was detected as a low-echogenic ring when the probe was moved cranially from the distal anal canal to the mid anal canal. The AVD in this study was measured and defined as the distance between the anal mucosa and the vaginal wall at the middle level of the anal canal. The measured AVD, in millimeters (mm), was documented in the women´s medical record under a specific keyword named "anovaginal distance".

The examiners had different proficiency in vaginal ultrasound. As a minimum training to be allowed to include women in the study, the midwives and doctors were trained individually in a defined education program. The education program was based on co-measuring the AVD with one of two experienced experts of AVD-measurement ( ref metodartikeln) . All examiners had to perform co-measurements in at least five women in term pregnancy. Each woman was, after informed consent, measured three times by both the expert and the examiner at education. These women were not included in the present study. The measured AVD values were not shared by the expert and the examiner. The AVD values were compared afterwards, outside the delivery room. In order to be given permission to independently measure the AVD, the examiners had to perform similar values (+/- five mm) as the expert, in five women. Proficiency was achieved among all examiners.

Information on measured AVD, maternal age, smoking status in early pregnancy, ethnicity, measured maternal weight and maternal height in early pregnancy was extracted from the digitalized medical records for every participant and manually registered in an anonymous research database. Gestational weight gain was defined as the difference between the registered weight in kilograms (kg) at the first antenatal visit to the antenatal care center, and the registered weight in term pregnancy at the delivery ward. If there was no registered weight at the delivery ward, the last registered weight at the antenatal care center (between gestational week 37-42) was used to calculate gestational weight gain.

The study population was then divided into three Body Mass Index (BMI) classes based on measured maternal weight and height in early pregnancy (gestational week 10-12); normal weight (BMI <25) , overweight (BMI 25-29.9) and obese (BMI ≥30) . Maternal obesity (BMI ≥30) was also subdivided into obesity class I (BMI 30-34.9) obesity class II (BMI 35-39.9) and obesity class III (BMI ≥40) as suggested by WHO.

The number of women included was based on a power calculation where the relevant difference in AVD between the BMI groups was set to be 10 mm and significance level were equals five percent. A stipulation that a difference of five mm in the AVD could be of clinical relevance was performed. The sample size in each BMI group was calculated to be at least 30 to reach a power of 80% to detect five mm difference in the AVD.

Statistical analyses were performed in order to compare background characteristics between different BMI groups using One-way Anova for continuous variables and X2-test for categorical variables. Post hoc tests were adjusted by the method of Tukey. A two-way Anova was used in order to analyze BMI groups and measurer simultaneously. A p-value of <0.05 was considered significant. Statistical analyses were performed using the Statistical Package for the Social Sciences (IBM SPSS Statistics, Chicago, IL, USA; version 22)

Conditions
Obesity, Pregnancy
Being tested
transperineal ultrasound
Medical subject headings
Obesity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • transperineal ultrasoundOther

    transperineal ultrasound was used by placing a vaginal ultrasound probe towards the vaginal distal wall pointing to the anus, measuring the anovaginal distance.

Study groups in NCT03149965
Study groupRoleWhat they receive
Body mass index 18.5-24.9Active comparatorThe anovaginal distance was measured with transperineal ultrasound. The standardized method consisted of placing the vaginal probe at a right angle to the posterior vaginal distal wall, and in a transversal scanning plane. The internal anal sphincter was detected as a low-echogenic ring when the probe was moved cranially from the distal anal canal to the mid anal canal. The anovaginal distance was defined as the distance between the anal mucosa and the vaginal wall at the middle level of the anal.
Receives: Other: transperineal ultrasound
body mass index ≥30ExperimentalThe anovaginal distance was measured with transperineal ultrasound. The standardized method consisted of placing the vaginal probe at a right angle to the posterior vaginal distal wall, and in a transversal scanning plane. The internal anal sphincter was detected as a low-echogenic ring when the probe was moved cranially from the distal anal canal to the mid anal canal. The anovaginal distance was defined as the distance between the anal mucosa and the vaginal wall at the middle level of the anal.
Receives: Other: transperineal ultrasound

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. anovaginal distance

    millimeter

    Measured: five minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 May 2017
  2. Study start2 Oct 2014
  3. Primary completion31 Mar 2016
  4. Study completion31 Mar 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Non-randomised
Intervention model
Parallel groups
Model description
prospective cohort study
Masking
None (open label)
Enrolment
207 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03149965
Sponsor's protocol ID
930209ec
Acronym
AVD
Status last verified
May 2017
First submitted
9 May 2017
Last updated
16 May 2017
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Hjertberg L, Uustal E, Pihl S, Blomberg M. Maternal Body Mass Index and Anovaginal Distance in Active Phase of Term Labor. Biomed Res Int. 2018 Mar 7;2018:1532949. doi: 10.1155/2018/1532949. eCollection 2018.

    PubMed 29707565

Questions about this trial

What is this clinical trial studying?

A study testing transperineal ultrasound in people with Obesity and Pregnancy, run by Linkoeping University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 May 2017. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

anovaginal distance (time frame: five minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03149965, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 May 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in